Under construction – not a live service

Skip to content

Frontlight Research

Institution

London Health Sciences Centre

London, CanadahealthcareWebsite

Also known as: LHSU

160running trials
59closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
NCT07858331· Phase 4· Source
Not yet recruiting
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
NCT07831122· Phase 1· Source
Not yet recruiting
A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer
NCT07920549· Phase 2/3· Source
Not yet recruiting
The BASIC-S Feasibility Study for Vascular Risk Reduction
NCT07755631· Source
Recruiting
TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS
NCT07893964· Phase 2· Source
Not yet recruiting
Trauma Therapy for Weight-Based Bullying in Children
NCT07685990· Source
Not yet recruiting
MICRO-ultrasound Guided Prostate SBRT
NCT07737457· Source
Not yet recruiting
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
NCT07680322· Phase 2· Source
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007· Phase 2· Source
Recruiting
Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial
NCT07300566· Source
Not yet recruiting
Staph Nasal Decolonization to Improve Function and Feeding
NCT07524894· Phase 2· Source
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892· Phase 2/3· Source
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604· Phase 3· Source
Recruiting
129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
NCT07192016· Phase 4· Source
Recruiting
Restrictive Fluid Management In Liver Transplantation (REFIL)
NCT07695363· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Source
Not yet recruiting
FMT in Triple Negative Breast Cancer Guided by ctDNA
NCT07292142· Phase 1/2· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Source
Not yet recruiting
SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease
NCT07066163· Source
Recruiting
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
NCT07272902· Source
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Source
Recruiting
Oral Carnitine in Heart Failure Patients
NCT07201714· Early phase 1· Source
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101· Phase 2· Source
Recruiting
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
NCT07027436· Phase 3· Source
Not yet recruiting
Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy
NCT07076914· Phase 2· Source
Active, not recruiting
Study of COYA 302 for the Treatment of ALS
NCT07161999· Phase 2/3· Source
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· Phase 3· Source
Recruiting
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
NCT06942039· Early phase 1· Source
Recruiting
DIALysis With EXpanded Solute Removal
NCT06660277· Source
Recruiting
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119· Phase 1· Source
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519· Phase 3· Source
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· Phase 2/3· Source
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497· Phase 3· Source
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· Phase 3· Source
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· Phase 3· Source
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· Phase 3· Source
Recruiting
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
NCT06337838· Phase 3· Source
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· Phase 3· Source
Recruiting
The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
NCT06850766· Source
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· Phase 3· Source
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· Source
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165· Phase 1· Source
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648· Source
Not yet recruiting
Genomic First Testing in Chronic Kidney Disease
NCT06794567· Source
Recruiting
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease
NCT05986318· Phase 2· Source
Not yet recruiting
Surgery and Reducing Ionizing Radiation of the Unknown Primary
NCT06578871· Phase 2· Source
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Source
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· Phase 3· Source
Recruiting
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
NCT05272826· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Chronic kidney disease8 recruiting
Lung cancer7 recruiting
Crohn's disease6 recruiting
Obesity5 recruiting
Prostate cancer5 recruiting
Ulcerative colitis4 recruiting
Atrial fibrillation3 recruiting
Childhood cancers3 recruiting
Colorectal cancer3 recruiting
Epilepsy3 recruiting
Head and neck cancer3 recruiting
Heart failure3 recruiting
Liver and biliary tract cancer3 recruiting
Migraine3 recruiting
Multiple myeloma3 recruiting
Stroke3 recruiting
ALS (motor neurone disease)2 recruiting
Alzheimer disease2 recruiting
Cervical cancer2 recruiting
Coronary artery disease2 recruiting
Parkinson disease2 recruiting
Asthma1 recruiting
Autism1 recruiting
Bladder cancer1 recruiting
Chronic lymphocytic leukaemia1 recruiting
COPD1 recruiting
Endometrial cancer1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Gastric and esophageal cancer1 recruiting
Glioblastoma1 recruiting
Haemophilia1 recruiting
High blood pressure1 recruiting
Hypertrophic cardiomyopathy1 recruiting
IgA nephropathy1 recruiting
Myelodysplastic syndromes1 recruiting
Neuroblastoma1 recruiting
Neuroendocrine tumours1 recruiting
Ovarian cancer1 recruiting
Pancreatic cancer1 recruiting
Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Source
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Source
Completed
Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
NCT06203977· Phase 2· Source
Completed
Real-World Effectiveness of Mavacamten in Canada
NCT06338202· Source
Completed
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· Phase 2· Source
Completed
The Extended CTA for the Successful Screening of Cardioaortic Thrombus in Acute Ischemic Stroke and TIA (DAYLIGHT) Trial
NCT05522244· Source
Completed
Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend
NCT05118893· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Source
Completed
TESTING -ON Post-Trial ObservatioNal Cohort Study
NCT05434325· Source
Completed
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063· Phase 3· Source
Completed
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245· Phase 2· Source
Completed
Clinic to Community© Program for Adults With Epilepsy Admitted to Emergency Departments
NCT04248920· Source
Terminated
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
NCT05033314· Phase 3· Source
Completed
Virtual Reality for Port-a-Cath Access
NCT04931745· Source
Completed
Radioligand fOr locAl raDiorecurrent proStaTe cancER
NCT05230251· Phase 1/2· Source
Completed
Same Day Discharge for Wedge Resection
NCT05067738· Source
Completed
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
NCT04779307· Phase 3· Source
Terminated
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
NCT04948645· Phase 1· Source
Completed
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
NCT04299464· Phase 2· Source
Terminated
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
NCT04632940· Phase 3· Source
Completed
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
NCT04053842· Phase 2· Source
Completed
Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.
NCT04644822· Phase 3· Source
Completed
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
NCT04266795· Phase 2· Source
Completed
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
NCT04670016· Source
Completed
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
NCT04303780· Phase 3· Source
Completed
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04182204· Phase 3· Source
Completed
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
NCT04029480· Phase 3· Source
Completed
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
NCT03832998· Phase 3· Source
Completed
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT03904693· Phase 3· Source
Completed
Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study
NCT03836417· Source
Completed
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
NCT03939689· Phase 2· Source
Completed
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
NCT03594110· Phase 3· Source
Completed
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
NCT03713593· Phase 3· Source
Completed
PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer
NCT03455608· Source
Completed
PSMA-PET Registry for Recurrent Prostate Cancer
NCT03718260· Source
Completed
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449· Phase 3· Source
Completed
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NCT03511664· Phase 3· Source
Terminated
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT03452137· Phase 3· Source
Completed
Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry
NCT03048825· Phase 3· Source
Completed
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
NCT03555422· Phase 3· Source
Completed
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
NCT03201965· Phase 3· Source
Completed
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
NCT03173560· Phase 2· Source
Completed
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
NCT03206021· Phase 1· Source
Completed
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· Phase 3· Source
Completed
Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia
NCT03376438· Source
Completed
Undiagnosed COPD and Asthma Population Study (UCAP)
NCT03148210· Source
Completed
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
NCT03040999· Phase 3· Source
Completed
CardiAMP™ Cell Therapy for Heart Failure Trial
NCT02438306· Phase 3· Source
Completed
Antiarrhythmics or Ablation for Ventricular Tachycardia 2
NCT02830360· Phase 4· Source

Trial sites

Institution data: ROR 037tz0e16 (CC0-1.0)Updated 7 Nov 2026

Report an error